Radiopharm's 18F-RAD101 PET shows 93.5% MRI agreement in interim Phase 2b brain metastasis data
Interim results presented at SNO show high concordance with contrast-enhanced MRI and no serious treatment-emergent adverse events, with specificity data due in the first quarter of 2027.
Radiopharm Theranostics has reported interim Phase 2b data for its PET imaging agent 18F-RAD101 in patients with suspected recurrent brain metastases after radiotherapy. The results were presented at the Society for Neuro-Oncology meeting, held 12-15 November 2026, and announced by the company on 16 November.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Radiopharm Theranostics Ltd ↗
Article written by VigiEye from the official source (Radiopharm Theranostics Ltd). Claims are the company's own. AI-assisted; check the source before acting.